Ani Pharmaceuticals Inc (ANIP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ANIP Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Ani Pharmaceuticals Inc's cash-generating activities.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
6 Months
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income104.63
Depreciation & amortization40.56
Amortization of Other Assets36.82
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges-0.80
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.13
Research and Development in Process0.00
Gain (Loss) on Disposition of Other Assets0.00
Share-based Compensation21.60
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Excess Consideration Paid Over Fair Value-
Increase Decrease In Accrued Compensation Liabilities-
Increase Decrease Accrued Government Rebates-4.74
Operating Lease Right Of Use Asset Amortization Expense0.45
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability Cash Flow-0.18
Increase Decrease In Royalty Payable-14.66
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable5.87
Increase (Decrease) in Accounts Payable4.24
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense7.65
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-105.64
Discontinued operations0.00
Net Cash flow from Operating Activities115.04
Investing Activities
Capital Expenditures-14.38
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Indefinitelived Intangible Assets Acquired-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-14.38
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-8.13
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-18.06
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.08
Proceeds From Issuance Of Common Stock By Underwritten Public Offering-
Payments To Fractional Share Payout-
Payments For Fractional Share Payout-
Repayments Of Short Term Convertible Debt-
Payment For Treasury Stock Purchases For Restricted Stock Vestings And Forfeitures-
Cash And Cash Equivalents And Restricted Cash And Cash Equivalents Current And Noncurrent-
Restricted Cash And Cash Equivalents Noncurrent-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents285.62
Payments Of Debt Issuance Costs And Convertible Debt Repurchase Costs-
Proceeds From Lines Of Credit Long Term-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-26.26
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow100.67
Total Cash Flow74.63
4 historic quarters locked

Sign in to unlock the full Ani Pharmaceuticals Inc cash flow history.

About Ani Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001023024-26-000069

Figures are derived from filed reports and may be restated. Historical data is subject to revision.